Effect of Adherence as Measured by MEMS, Ritonavir Boosting, and CYP3A5 Genotype on Atazanavir Pharmacokinetics in Treatment-Naive HIV-Infected Patients-Reference-Cited by-同舟云学术

Effect of Adherence as Measured by MEMS, Ritonavir Boosting, and CYP3A5 Genotype on Atazanavir Pharmacokinetics in Treatment-Naive HIV-Infected Patients

Published:2012-10-03 Issue:5 Volume:92 Page:575-583
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:
Short-container-title:Clin Pharmacol Ther

Author:

Savic R M,Barrail-Tran A,Duval X,Nembot G,Panhard X,Descamps D,Verstuyft C,Vrijens B,Taburet A-M,Goujard C,Mentré F

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology

Reference38 articles.

1. Atazanavir: a novel HIV-1 protease inhibitor

2. Atazanavir

3. Population Pharmacokinetics of Atazanavir in Patients with Human Immunodeficiency Virus Infection

4. Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacokinetic, Pharmacodynamic, Preclinical and Clinical Models for Evaluation of Nanoparticles;Pharmacokinetics and Pharmacodynamics of Novel Drug Delivery Systems: From Basic Concepts to Applications;2024

2. Pharmacokinetic Model of Tenofovir and Emtricitabine and Their Intracellular Metabolites in Patients in the ANRS 134-COPHAR 3 Trial Using Dose Records;Antimicrobial Agents and Chemotherapy;2023-05-17

3. Will the Use of Pharmacogenetics Improve Treatment Efficiency in COVID-19?;Pharmaceuticals;2022-06-13

4. Pharmacogenetics-based population pharmacokinetic analysis for dose optimization of ritonavir-boosted atazanavir in Thai adult HIV-infected patients;Expert Review of Clinical Pharmacology;2021-11-26

5. Developing Tools to Evaluate Non-linear Mixed Effect Models: 20 Years on the npde Adventure;The AAPS Journal;2021-05-19